AdverseEvents' Special Report: Examining the Comparative Safety of Type 2 Diabetes Drugs

AdverseEvents' Special Report: Examining the Comparative Safety of Type 2 Diabetes Drugs

Type 2 Diabetes Drugs Safety Review: Byetta Has Best Safety Profile, Nesina Shows Worst Safety Profile

Type 2 Diabetes affects approximately 230 million people worldwide and incidence is growing at an alarming rate. To address this epidemic, new drugs are quickly coming to market. Pre-marketing clinical trials are the established means for determining a drug's safety and efficacy during the approval process, but they are by no means perfect.  When a new drug comes to market a more heterogeneous population uses it and, accordingly, real-world side effects begin to appear.

As such, AdverseEvents, Inc. conducted a comprehensive comparative safety analysis of current FDA approved Type 2 Diabetes drugs and reports the findings in the downloadable Special Report: Examining the Comparative Safety of Type 2 Diabetes Drugs.

Download Special Report: Examining the Comparative Safety of Type 2 Diabetes Drugs to:

Top Line Summary:
The newly approved SGLT-2 inhibitors, are as expected, associated with elevated urinary infection risks, but may also be linked to more serious adverse events
DPP-4 inhibitors may be linked to more serious side effects than is widely believed
alogliptin (Nesina; Takeda) has a higher risk profile than other drugs on market
exenatide (Byetta; AstraZeneca and Bristol-Myers Squibb) has the best safety profile of the diabetes drugs on market
Drugs included in the analysis are:
GLP-1 Agonists
exenatide long acting release (Bydureon; AstraZeneca and Bristol-Myers Squibb)
exenatide (Byetta; AstraZeneca and Bristol-Myers Squibb)
liraglutide (Victoza; Novo Nordisk)

DPP-4 Inhibitors
sitagliptin metformin (Janumet; Merck)
sitagliptin (Januvia; Merck)
linagliptin metformin (Jentadueto; Boehringer Ingelheim and Eli Lilly)
alogliptin (Nesina; Takeda)
saxagliptin (Onglyza; AstraZeneca and Bristol-Myers Squibb)
linaglipitin (Tradjenta; Boehringer Ingelheim and Eli Lilly)

SGLT-2 Inhibitors
dapagliflozin (Farxiga; AstraZeneca and Bristol-Myers Squibb)
canagliflozin (Invokana; Johnson & Johnson)

For additional information or interview requests please contact: [email protected]

About AdverseEvents
AdverseEvents, Inc. (AEI) is a California-based healthcare informatics company that improves patient safety and reduces systemic healthcare costs through the comprehensive analysis of post-marketing drug side effect data. Utilizing data-mining and analysis technology, through its proprietary RxSuite™ of analytics, AEI makes post-marketing drug safety data accessible, actionable, and predictable.

In addition to managed care organizations, AEI also provides services to enterprise markets including the pharmaceutical industry and financial institutions.

Neither AdverseEvents, nor its officers or employees have been directly compensated by any party for the preparation of this report. The inclusion of a particular company, drug, class or indication in this report is determined wholly by our quantitative signaling and scoring systems along with our qualitative analysis work.  The inclusion or exclusion of any drug, company, or indication has not and will not be influenced by any third party, including any clients of AdverseEvents. Please download the white paper to review the Disclaimer in its entirety.

Read the full report here (PDF)

Suggested Articles

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.